drugset / Trial / NCT01588626

Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers

NCT01588626

Phase 1 Completed 12 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the pharmacokinetics of AZD6140 and its active metabolite, safety, tolerability of AZD6140 following single administration in healthy male Japanese volunteers.

Timeline

Start
2012-05
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 90 mg Oral

Indications

No indication recorded.